To the full analysis
Alnylam Pharmaceuticals stock: growth
ALNYAlnylam Pharmaceuticals reported $3.71B in revenue for fiscal 2025, up 65.2% on the prior year, up 49.8% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
29.6%
per year from 2006 to 2025, per share 20.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 49.8% | 56.9% | 29.6% |
| Revenue per share | 45.9% | 50.1% | 20.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $26.93M | −$34.61M | −$29.62M |
| 2007 | $50.9M | −$85.47M | $188.73M |
| 2008 | $96.16M | −$26.25M | $54.73M |
| 2009 | $100.53M | −$47.59M | −$77.09M |
| 2010 | $100.04M | −$43.52M | −$89.07M |
| 2011 | $82.76M | −$57.65M | −$88.36M |
| 2012 | $66.73M | −$106.01M | −$123.96M |
| 2013 | $47.17M | −$89.23M | −$72.66M |
| 2014 | $50.56M | −$360.4M | −$174.6M |
| 2015 | $41.1M | −$290.07M | −$202.09M |
| 2016 | $47.16M | −$410.11M | −$372.26M |
| 2017 | $89.91M | −$490.87M | −$487M |
| 2018 | $74.91M | −$761.5M | −$689.5M |
| 2019 | $219.75M | −$886.12M | −$418.58M |
| 2020 | $492.85M | −$858.28M | −$685.32M |
| 2021 | $844.29M | −$852.82M | −$718.07M |
| 2022 | $1.04B | −$1.13B | −$613.33M |
| 2023 | $1.83B | −$440.24M | $41.95M |
| 2024 | $2.25B | −$278.16M | −$42.59M |
| 2025 | $3.71B | $313.75M | $465.38M |
Revenue by segment
How Alnylam Pharmaceuticals, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Amvuttra$2.3B62%
- Net revenues from collaborations$553.4M15%
- Givlaari$308.5M8%
- Oxlumo$191.4M5%
- Royalty revenue$174.0M5%
- Onpattro$172.8M5%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Amvuttra | $2.31B | 62.3% |
| Net revenues from collaborations | $553.37M | 14.9% |
| Givlaari | $308.49M | 8.3% |
| Oxlumo | $191.44M | 5.2% |
| Royalty revenue | $174.02M | 4.7% |
| Onpattro | $172.79M | 4.7% |
| Total revenue | $3.71B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 13 Feb 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.